COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Centers for Disease Control and Prevention issued preliminary guidance for the development of forthcoming contact tracing apps that can help slow the spread of COVID-19.
The Food and Drug Administration said it is adopting more stringent standards for COVID-19 antibody tests.
The Food and Drug Administration issued Gilead Sciences an emergency use authorization for the investigational antiviral drug remdesivir to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.
The Food and Drug Administration issued Gilead Sciences an emergency use authorization for the investigational antiviral drug remdesivir to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.
The Food and Drug Administration issued Gilead Sciences an emergency use authorization for the investigational antiviral drug remdesivir to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.
An independent commission will assess the response to COVID-19 and offer recommendations to nursing homes, the Centers for Medicare & Medicaid Services announced.
The Food and Drug Administration yesterday approved for emergency use a ventilator specially developed by the National Aeronautics and Space Administration to treat COVID-19 patients.
The Centers for Medicare & Medicaid Services released a number of new waivers related to COVID-19. The waivers apply nationwide and are generally retroactive to March 1, 2020.
The Centers for Medicare & Medicaid Services (CMS) yesterday released a number of new waivers related to COVID-19.
Statement on additional regulatory waivers from CMS from AHA President and CEO Rick Pollack.